SCHEMBL1032767

SCHEMBL1032767

COc1nc(NC2CCC(C)CC2)ncc1-c1ccc(OC(C)C)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 1/20 0.43
MAPK8 P45983 3/20 0.38
CDK4 P11802 1/20 0.38
GSK3B P49841 1/20 0.38
MAPK6 Q16659 4/20 0.37
ADORA2A P29274 1/20 0.36
ADORA2B P29275 1/20 0.36
ADORA1 P30542 1/20 0.36
MAP4K4 O95819 1/20 0.36
MAPK1 P28482 1/20 0.36
AXL P30530 1/20 0.36
TYRO3 Q06418 1/20 0.36
CDK9 P50750 1/20 0.35
MAPK10 P53779 3/20 0.35
GABBR2 O75899 1/20 0.35
GABBR1 Q9UBS5 1/20 0.35
MAPK9 P45984 1/20 0.35
ALDH1A1 P00352 2/20 0.34
SYK P43405 1/20 0.34
JUN P05412 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12125236 1.00 GRM5 (0.43) GRM5MAPK8CDK4GSK3BMAPK6
SCHEMBL1032768 1.00 GRM5 (0.43) GRM5MAPK8CDK4GSK3BMAPK6
SCHEMBL1028883 0.90 GALR2 (0.44) GRM5MAPK8MAPK6ADORA2AADORA2B
SCHEMBL1028884 0.90 GALR2 (0.44) GRM5MAPK8MAPK6ADORA2AADORA2B
SCHEMBL1033501 0.90 GALR2 (0.43) CDK4ADORA1AXLTYRO3MAPK10
SCHEMBL1032397 0.89 GRM5 (0.41) GRM5MAPK8CDK4GSK3BMAPK6
SCHEMBL1032401 0.89 GRM5 (0.41) GRM5MAPK8CDK4GSK3BMAPK6
SCHEMBL1332938 0.88 GRM5 (0.40) GRM5CDK4GSK3BMAPK6ADORA2A
SCHEMBL1332864 0.88 GRM5 (0.40) GRM5MAPK8CDK4GSK3BMAPK6
SCHEMBL1332939 0.88 GRM5 (0.40) GRM5CDK4GSK3BMAPK6ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513242-B2 Pyrimidine compounds and methods of making and using same CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CYSTIC FIBROSIS FOUNDATION 2011-11-17 US disclosed
WO-2011008931-A2 ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281873-A1 Pyrimidine Compounds and Methods of Making and Using Same CFTR, GPR17, TYMS GRM5 2764/4885MAPK8 3599/4885CDK4 2340/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.